Stockscreener 앱 받기
0.8077
2.37%
0.0187
시장 영업 전:
.81
0.0023
+0.28%
전일 마감가:
$0.789
열려 있는:
$0.79
하루 거래량:
78,981
Relative Volume:
0.55
시가총액:
$22.62M
수익:
-
순이익/손실:
$-61.28M
주가수익비율:
-0.3688
EPS:
-2.19
순현금흐름:
$-46.46M
1주 성능:
+3.43%
1개월 성능:
-16.73%
6개월 성능:
-52.21%
1년 성능:
-28.52%
1일 변동 폭
$0.7699
$0.82
1주일 범위
$0.7606
$0.8288
52주 변동 폭
$0.76
$2.57
Nextcure Inc Stock (NXTC) Company Profile
명칭
Nextcure Inc
전화
240-399-4900
주소
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
NXTC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
0.8077 | 22.62M | 0 | -61.28M | -46.46M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-11-04 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2022-03-01 | 개시 | Ladenburg Thalmann | Buy |
| 2021-03-05 | 업그레이드 | Truist | Hold → Buy |
| 2021-01-15 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-07-16 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2020-07-13 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-07-13 | 다운그레이드 | SunTrust | Buy → Hold |
| 2020-06-01 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-06-01 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2020-05-26 | 개시 | JMP Securities | Mkt Outperform |
| 2020-03-24 | 개시 | The Benchmark Company | Buy |
| 2020-03-02 | 개시 | ROTH Capital | Buy |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-12-05 | 개시 | Needham | Buy |
| 2019-11-26 | 개시 | BTIG Research | Buy |
| 2019-07-09 | 개시 | BofA/Merrill | Buy |
| 2019-06-03 | 개시 | Morgan Stanley | Overweight |
| 2019-06-03 | 개시 | Piper Jaffray | Overweight |
모두보기
Nextcure Inc 주식(NXTC)의 최신 뉴스
Geode Capital Management LLC Acquires 27,812 Shares of NextCure, Inc. (NASDAQ:NXTC) - Defense World
Jane Street Group LLC Has $125,000 Holdings in Metalla Royalty & Streaming Ltd. (NYSEMKT:MTA) - Defense World
NextCure Initiates Phase 1 Study for B7-H4 ADC Therapy to Treat Multiple Cancers_ - Defense World
LigaChem Biosciences doses first patient in phase 1 trial of LNCB74 cancer drugCHOSUNBIZ - 조선비즈
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 as Therapeutic for Treating Multiple Cancers - Marketscreener.com
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers - The Manila Times
NextCure Advances Cancer Treatment: First Patient Dosed in LNCB74 Phase 1 Trial - StockTitan
Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews
NextCure stock hits 52-week low at $0.87 amid market challenges - Investing.com Australia
NextCure stock hits 52-week low at $0.87 amid market challenges By Investing.com - Investing.com South Africa
NextCure stock hits 52-week low at $0.99 amid market challenges By Investing.com - Investing.com South Africa
NextCure stock hits 52-week low at $0.99 amid market challenges - Investing.com India
The Buckle, Inc. Announces Dividend PayoutsKearney, NE — The Buckle, Inc. (NYSE: BKE) disclosed plans for upcoming shareholder dividend payments following the quarterly meeting of its Board of Directors on December 9, 2024. The company greenlighte - Defense World
FDA clears IND for B7-H4-targeting ADC - BioWorld Online
NextCure Announces Acceptance of IND Application for LNCB74 - The Manila Times
NextCure, Inc. Announces Acceptance of IND Application for LNCB74 - Marketscreener.com
NextCure's Cancer Drug LNCB74 Secures FDA IND Approval for Phase 1 Clinical Trials - StockTitan
NextCure stock hits 52-week low at $1.00 amid market challenges - Investing.com Australia
NextCure stock hits 52-week low at $1.00 amid market challenges By Investing.com - Investing.com South Africa
NextCure Advances with New Cancer Drug Application - TipRanks
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference - The Manila Times
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta - The Manila Times
NextCure's NC605 Shows 90% Fracture Prevention in Breakthrough Bone Disease Study | NXTC Stock News - StockTitan
Logos Global Management LP Reduces Stake in NextCure Inc - GuruFocus.com
Affinity Asset Advisors, LLC Increases Stake in NextCure Inc - GuruFocus.com
Here's Why We're Watching NextCure's (NASDAQ:NXTC) Cash Burn Situation - Simply Wall St
NextCure Reports Improved Financial Performance and Strategic Focus - TipRanks
National Presto Industries, Inc. (NYSE:NPK) Shares Sold by State of Alaska Department of Revenue - Defense World
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results - The Manila Times
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting - The Manila Times
NextCure Reports Preclinical Data for LNCB74 and Additional Clin - WICZ
NextCure (NASDAQ:NXTC) Shares Down 3.6% – Here’s Why - Defense World
Intuitive Surg Inc (ISRG-Q) QuotePress Release - The Globe and Mail
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting - The Manila Times
Elevation Capital Advisory LLC Purchases New Shares in Vanguard Information Technology ETF (NYSEARCA:VGT) - americanbankingnews.com
Affinity Asset Advisors LLC Invests $432,000 in NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) - Defense World
NextCure, Inc. (NASDAQ:NXTC) Shares Purchased by Logos Global Management LP - Defense World
Next plc Executes Share Buyback Program - TipRanks
Nexteq PLC Announces Share Buyback and Voting Rights Update - TipRanks
Next PLC Executes Share Buy-Back for Cancellation - TipRanks
Next plc Conducts Share Buyback and Cancellation - TipRanks
Next lifts profit guidance to almost £1bn - Investors Chronicle
Next PLC’s Fresh Guidance Lift, Overseas Plans Boost Shares - The Wall Street Journal
Next PLC Impresses Investors with Yet Another Guidance Upgrade - TipRanks
Next is approaching a historic profit landmark- what is driving this growth? - Proactive Investors Australia
Next Shares Rise 3% As Full-Year Estimates Hiked - Forbes
Next shares rise on upbeat full-year profit outlook By Investing.com - Investing.com South Africa
Record high for Next shares after guidance raised again - Interactive Investor
Next Lifts Profit Target Again as Autumn Fashion Sales Surge - BNN Bloomberg
UK's Next raises forecast to put 1 billion pound profit in sight - Reuters
Nextcure Inc (NXTC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):